Although the definition of remission varies, the goal of IBD treatment is to achieve and sustain remission.
Bias extends beyond skin color to the assumptions physicians might make about patients.
Medical ethicist David J. Alfandre, MD, MS, addresses the quandary of deciding who gets priority in the allocation of healthcare resources, an issue of particular relevance today now that COVID-19 vaccinations are underway.
Monisha Sharma, PhD, and Charlene Dewey, MD, provide insight into the current landscape that leads to physician burnout and the next steps to combat it.
The American Gastroenterological Association commissioned an expert review to identify best practice advice for treating patients with nonalcoholic fatty liver disease.
In September, as doctors prepared for a fall and winter COVID-19 surge across the U.S., they sounded alarms about inadequate supplies of the antiviral medication remdesivir to treat their patients. But that supply concern seems to have been addressed: Gilead, remdesivir’s U.S. manufacturer, confirmed that they are “meeting real-time, global demand” in an email to…
Although the emergence of COVID-19 initially called the continuation of inflammatory bowel disease (IBD) therapy into question, treatment has proceeded — albeit with added considerations.
Early video capsule endoscopy may be an appropriate means for frontline evaluation of gastrointestinal bleeding.
In gastroenterology, legal concerns encompass procedural skill and use of non-technical strengths such as communication and decision making.
Paul J. Limburg, MD, highlights the significance of the United States Preventive Services Task Force’s draft guidance for colorectal cancer screening.
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
When to perform PP represents a clinical conundrum in gastroenterology, but consulting certain quality indicators can help guide PP decisions.
The American College of Gastroenterology Annual Scientific Meeting will observe its 88th annual iteration from October 26 to October 28, 2020.
Recent data trends have demonstrated declining CRC incidence in older patients, and a corresponding increase in patients in their 40s.
The US Department of Health and Human Services’ Office for Civil Rights has levied big fines against medical organizations who failed to adhere to HIPAA requirements to release medical records to patients at their request.
The COVID-19 pandemic has served as a catalyst for clinicians who previously put off purchasing insurance.
When talking about work issues, Dr Bernstein recommends trying not to focus too much on how awful things are because it can be disheartening.
Phase 2 clinical trial shows promising result for dabrafenib and trametinib combination in patients with advanced cholangiocarcinoma with a BRAFV600E mutation.
A team of researchers recently evaluated serum concentrations of persistent organic pollutants to determine how they may affect celiac disease.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.